MedMen Enterprises
Market Cap
CA$223.8m
Last Updated
2020/03/29 06:42 UTC
Data Sources
Company Financials +
Executive Summary
MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis company in the United States.
Rewards
Risk Analysis
Shareholders have been substantially diluted in the past year
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Limited growth and overvalued.
Similar Companies
Share Price & News
How has MedMen Enterprises's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MMEN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
68.0%
MMEN
25.2%
CA Pharmaceuticals
6.4%
CA Market
1 Year Return
-89.8%
MMEN
-73.7%
CA Pharmaceuticals
-25.5%
CA Market
Return vs Industry: MMEN underperformed the Canadian Pharmaceuticals industry which returned -73.2% over the past year.
Return vs Market: MMEN underperformed the Canadian Market which returned -25.3% over the past year.
Shareholder returns
| MMEN | Industry | Market | |
|---|---|---|---|
| 7 Day | 68.0% | 25.2% | 6.4% |
| 30 Day | 27.3% | -16.9% | -22.6% |
| 90 Day | -26.3% | -29.3% | -26.8% |
| 1 Year | -89.8%-89.8% | -73.7%-73.7% | -23.2%-25.5% |
| 3 Year | n/a | -15.1%-15.7% | -15.7%-23.5% |
| 5 Year | n/a | 208.9%208.9% | -3.1%-17.4% |
Price Volatility Vs. Market
How volatile is MedMen Enterprises's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall St
Are Insiders Buying MedMen Enterprises Inc. (CSE:MMEN) Stock?1 month ago | Simply Wall St
Are Investors Undervaluing MedMen Enterprises Inc. (CSE:MMEN) By 26%?Valuation
Is MedMen Enterprises undervalued compared to its fair value and its price relative to the market?
0.3x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: MMEN (CA$0.42) is trading above our estimate of fair value (CA$0.23)
Significantly Below Fair Value: MMEN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MMEN is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: MMEN is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MMEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MMEN is good value based on its PB Ratio (0.3x) compared to the CA Pharmaceuticals industry average (1x).
Next Steps
Future Growth
How is MedMen Enterprises forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
64.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MMEN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MMEN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MMEN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MMEN's revenue (30.4% per year) is forecast to grow faster than the Canadian market (3.9% per year).
High Growth Revenue: MMEN's revenue (30.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MMEN's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has MedMen Enterprises performed over the past 5 years?
-18.2%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: MMEN is currently unprofitable.
Growing Profit Margin: MMEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if MMEN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare MMEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MMEN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-23.4%).
Return on Equity
High ROE: MMEN has a negative Return on Equity (-255.38%), as it is currently unprofitable.
Next Steps
Financial Health
How is MedMen Enterprises's financial position?
Financial Position Analysis
Short Term Liabilities: MMEN's short term assets ($151.2M) do not cover its short term liabilities ($188.8M).
Long Term Liabilities: MMEN's short term assets ($151.2M) do not cover its long term liabilities ($537.4M).
Debt to Equity History and Analysis
Debt Level: MMEN's debt to equity ratio (197.2%) is considered high.
Reducing Debt: Insufficient data to determine if MMEN's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: MMEN has a high level of physical assets or inventory.
Debt Coverage by Assets: MMEN's debt is not covered by short term assets (assets are 0.7x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MMEN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MMEN has less than a year of cash runway if free cash flow continues to reduce at historical rates of -77% each year
Next Steps
Dividend
What is MedMen Enterprises's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MMEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MMEN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MMEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MMEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MMEN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
0.8yrs
Average management tenure
CEO
Ryan Lissack (40yo)
0.083
Tenure
Mr. Ryan Lissack is a Chief Executive Officer of MedMen Enterprises Inc., since 2020. He served as an Interim Chief Executive Officer of MedMen Enterprises Inc., since February 1, 2020 until 2020 and serve ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 1.58yrs | no data | no data | |
| Co-Founder & Director | 1.83yrs | US$7.35m | 0.61% $1.4m | |
| Co-founder & Chief Brand Officer | no data | US$6.20m | 0.68% $1.5m | |
| Chief Executive Officer | 0.083yr | no data | no data | |
| Chief Financial Officer | 0.42yr | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior Vice President of Legal Affairs | no data | no data | no data | |
| Vice President of Communications | no data | no data | no data | |
| Senior VP of Marketing & Communications | 1.17yrs | no data | no data | |
| Chief Strategy Officer & Director | 0.083yr | no data | 0.82% $1.8m |
0.8yrs
Average Tenure
37yo
Average Age
Experienced Management: MMEN's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 1.58yrs | no data | no data | |
| Co-Founder & Director | 1.83yrs | US$7.35m | 0.61% $1.4m | |
| Chief Strategy Officer & Director | 0.083yr | no data | 0.82% $1.8m | |
| Independent Director | 0.083yr | no data | no data | |
| Director | 1.67yrs | US$56.25k | 0.053% $118.8k | |
| Independent Director | 0.083yr | no data | no data |
0.8yrs
Average Tenure
41yo
Average Age
Experienced Board: MMEN's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MMEN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 69.8%.
Top Shareholders
Company Information
MedMen Enterprises Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: MedMen Enterprises Inc.
- Ticker: MMEN
- Exchange: CNSX
- Founded: 2010
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$223.768m
- Market Cap: CA$129.902m
- Shares outstanding: 622.31m
- Website: https://www.medmen.com
Number of Employees
Location
- MedMen Enterprises Inc.
- 10115 Jefferson Boulevard
- Culver City
- California
- 90232
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MMEN | CNSX (Canadian National Stock Exchange) | Yes | Class B Subordinate Voting Shares | CA | CAD | May 2018 |
| 0JS | BST (Boerse-Stuttgart) | Yes | Class B Subordinate Voting Shares | DE | EUR | May 2018 |
| MMNF.F | OTCPK (Pink Sheets LLC) | Yes | Class B Subordinate Voting Shares | US | USD | May 2018 |
| 0JS | DB (Deutsche Boerse AG) | Yes | Class B Subordinate Voting Shares | DE | EUR | May 2018 |
Biography
MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis company in the United States. The company cultivates, produces, and retails recreational and medicinal cannabis under the [statemade], LuxLyte, and MedMen Red brand names. It operates 33 retail stores in nine states. The company was founded in 2010 and is headquartered in Culver City, California.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/03/29 06:42 |
| End of Day Share Price | 2020/03/27 00:00 |
| Earnings | 2019/12/28 |
| Annual Earnings | 2019/06/29 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.